(NASDAQ: VSTM) Verastem's forecast annual revenue growth rate of 41.31% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.1%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.3%.
Verastem's revenue in 2026 is $87,526,000.On average, 11 Wall Street analysts forecast VSTM's revenue for 2026 to be $10,506,264,790, with the lowest VSTM revenue forecast at $9,068,117,347, and the highest VSTM revenue forecast at $11,915,431,932. On average, 11 Wall Street analysts forecast VSTM's revenue for 2027 to be $14,828,857,829, with the lowest VSTM revenue forecast at $11,910,903,760, and the highest VSTM revenue forecast at $17,896,241,576.
In 2028, VSTM is forecast to generate $23,071,942,229 in revenue, with the lowest revenue forecast at $18,140,762,867 and the highest revenue forecast at $27,479,664,903.